Want to see COGT full AI Analyst Report?
Total Valuation
Cogent Biosciences has a market cap or net worth of $6.51B. The enterprise value is $5.75B.
Market Cap$6.51B
Enterprise Value$5.75B
Share Statistics
Cogent Biosciences has 170,868,010 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding170,868,010
Owned by Insiders4.03%
Owned by Institutions44.21%
Financial Efficiency
Cogent Biosciences’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -38.09%.
Return on Equity (ROE)-0.52
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-38.09%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee0.00
Profits Per Employee-1.60M
Employee Count205
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cogent Biosciences is ―. Cogent Biosciences’s PEG ratio is -3.81.
PE Ratio―
PS Ratio0.00
PB Ratio3.77
Price to Fair Value3.77
Price to FCF-9.03
Price to Operating Cash Flow-9.17
PEG Ratio-3.81
Income Statement
In the last 12 months, Cogent Biosciences had revenue of 0.00 and earned -328.94M in profits. Earnings per share was -2.55.
Revenue0.00
Gross Profit-4.62M
Operating Income-333.36M
Pretax Income-328.94M
Net Income-328.94M
EBITDA-321.26M
Earnings Per Share (EPS)-2.55
Cash Flow
In the last 12 months, operating cash flow was -284.82M and capital expenditures -1.46M, giving a free cash flow of -286.27M billion.
Operating Cash Flow-284.82M
Free Cash Flow-286.27M
Free Cash Flow per Share-1.68
Dividends & Yields
Cogent Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change430.64%
50-Day Moving Average34.61
200-Day Moving Average31.69
Relative Strength Index (RSI)70.17
Average Volume (3m)2.19M
Important Dates
Cogent Biosciences upcoming earnings date is Aug 11, 2026, TBA (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Cogent Biosciences as a current ratio of 14.23, with Debt / Equity ratio of 39.27%
Current Ratio14.23
Quick Ratio14.23
Debt to Market Cap0.10
Net Debt to EBITDA0.18
Interest Coverage Ratio-108.87
Taxes
In the past 12 months, Cogent Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cogent Biosciences EV to EBITDA ratio is -7.29, with an EV/FCF ratio of -8.81.
EV to Sales0.00
EV to EBITDA-7.29
EV to Free Cash Flow-8.81
EV to Operating Cash Flow-8.86
Balance Sheet
Cogent Biosciences has $866.38M in cash and marketable securities with $238.65M in debt, giving a net cash position of $627.73M billion.
Cash & Marketable Securities$866.38M
Total Debt$238.65M
Net Cash$627.73M
Net Cash Per Share$3.67
Tangible Book Value Per Share$9.41
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cogent Biosciences is $52.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$52.43
Price Target Upside40.75% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast0.01%